


**Supplementary table 1: Definitions for interaction between KIR3DL1 and HLA-B allotypes in this experiment**

		KIR3DL1		
		*00701	*01502	*001
HLA-B	B*35:01	non	non	non
	B*44:03	strong	weak	weak
	B*52:01	weak	strong	strong

The above classification is defined by adopting the definition in previous clinical studies (see references 30, 31, and 34 in the main text). In brief, any pair that contains Bw6 is classified as non, 3DL1-low to Bw4-80I pairs and 3DL1-high to Bw4-80T pairs are classified as weak, and 3DL1-low to Bw4-80T pairs and 3DL1-high to Bw4-80I pairs are classified as strong.

## Figure S1



### *Supplementary figure 1: Pretreatment of NK cells with dasatinib increases CD107a expression levels*

(A) Representative flow cytometry contour plots showing the expression level of CD107a (as a marker of degranulation activity) in total NK cells. PBMCs were treated with DMSO or dasatinib for 24 hours at the indicated concentrations. After washing out of drugs, pre-treated PBMCs with or without co-incubation with K562 cells at an effector: target (E:T) ratio of 1: 1 were stained with anti-CD107a antibody. FSC, forward scatter. (B) The percentages of CD107a<sup>+</sup> NK cells are presented as the mean value of triplicate samples. Error bars show the standard error of the mean (SEM; ns, not significant; \*, P<0.05; \*\*, P<0.01; \*\*\*, P<0.001).